If the setback of the Expedition 3 study of solanezumab set their mood in the beginning, attendees at the 2016 Clinical Trials on Alzheimer’s Disease conference soon bucked up and voiced renewed determination to tackle this illness. Many took positive secondary outcomes and trends in this Phase 3 trial as a sign that this or more potent anti-amyloid drugs given earlier will make a bigger dent in the disease process. Short of major surprises, the meeting reaffirmed the sense that AD will only be slowed by deploying potent drugs at the right target (probably more than one), with the right dose, and certainly at the right time.
Patients on solanezumab saw small improvements on multiple secondary endpoints.
The tau aggregation inhibitor LMTM tanks in second Phase 3 trial for Alzheimer’s. The sponsor now plans to develop the “placebo.”
Biogen and Genentech rolled out more data from their Phase 1b trials, renewing hope that amyloid removal will work and shoring up dosing for Phase 3.
At CTAD, tau-PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
A few attempts at Alzheimer’s therapy claim hints of promise in early clinical trials, though several did not include placebo controls.